Swiss pharma group Novartis has said it will expand its US manufacturing and research and development with a $23bn investment over five years, as drugmakers reconfigure their supply chains as part of preparations for potential US tariffs.
瑞士制药集团诺华(Novartis)表示，将在未来5年内投资230亿美元，扩大其在美国的制造和研发。许多制药商正在重新配置供应链，以应对可能的美国关税。
您已阅读11%（314字），剩余89%（2633字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。